nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—uterine cervix—ovarian cancer	0.037	0.188	CbGeAlD
Pentazocine—EBP—uterus—ovarian cancer	0.0309	0.157	CbGeAlD
Pentazocine—EBP—female reproductive system—ovarian cancer	0.0277	0.141	CbGeAlD
Pentazocine—SIGMAR1—myometrium—ovarian cancer	0.0128	0.0653	CbGeAlD
Pentazocine—Decreased appetite—Altretamine—ovarian cancer	0.0128	0.0159	CcSEcCtD
Pentazocine—OPRK1—female reproductive system—ovarian cancer	0.0127	0.0648	CbGeAlD
Pentazocine—Asthenia—Altretamine—ovarian cancer	0.0106	0.0131	CcSEcCtD
Pentazocine—SIGMAR1—uterine cervix—ovarian cancer	0.00999	0.0508	CbGeAlD
Pentazocine—Dizziness—Altretamine—ovarian cancer	0.00973	0.0121	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Chlorambucil—ovarian cancer	0.00958	0.0119	CcSEcCtD
Pentazocine—SIGMAR1—decidua—ovarian cancer	0.00952	0.0484	CbGeAlD
Pentazocine—Vomiting—Altretamine—ovarian cancer	0.00935	0.0116	CcSEcCtD
Pentazocine—SIGMAR1—endometrium—ovarian cancer	0.00904	0.046	CbGeAlD
Pentazocine—Nausea—Altretamine—ovarian cancer	0.00874	0.0109	CcSEcCtD
Pentazocine—Cramp muscle—Topotecan—ovarian cancer	0.00853	0.0106	CcSEcCtD
Pentazocine—SIGMAR1—uterus—ovarian cancer	0.00833	0.0424	CbGeAlD
Pentazocine—Hallucination—Chlorambucil—ovarian cancer	0.00732	0.00911	CcSEcCtD
Pentazocine—OPRM1—testis—ovarian cancer	0.00731	0.0372	CbGeAlD
Pentazocine—SIGMAR1—bone marrow—ovarian cancer	0.00707	0.036	CbGeAlD
Pentazocine—Sweating—Topotecan—ovarian cancer	0.007	0.00871	CcSEcCtD
Pentazocine—Erythema multiforme—Chlorambucil—ovarian cancer	0.00696	0.00866	CcSEcCtD
Pentazocine—SIGMAR1—female gonad—ovarian cancer	0.00681	0.0347	CbGeAlD
Pentazocine—SIGMAR1—vagina—ovarian cancer	0.00677	0.0345	CbGeAlD
Pentazocine—Lightheadedness—Paclitaxel—ovarian cancer	0.00672	0.00836	CcSEcCtD
Pentazocine—SIGMAR1—testis—ovarian cancer	0.00604	0.0307	CbGeAlD
Pentazocine—Nystagmus—Epirubicin—ovarian cancer	0.00601	0.00748	CcSEcCtD
Pentazocine—Tremor—Chlorambucil—ovarian cancer	0.006	0.00747	CcSEcCtD
Pentazocine—Flushing—Melphalan—ovarian cancer	0.00595	0.00741	CcSEcCtD
Pentazocine—Agitation—Chlorambucil—ovarian cancer	0.00589	0.00733	CcSEcCtD
Pentazocine—Chills—Topotecan—ovarian cancer	0.00588	0.00732	CcSEcCtD
Pentazocine—Agranulocytosis—Vinorelbine—ovarian cancer	0.00583	0.00725	CcSEcCtD
Pentazocine—Visual disturbance—Paclitaxel—ovarian cancer	0.00575	0.00716	CcSEcCtD
Pentazocine—Lightheadedness—Docetaxel—ovarian cancer	0.00569	0.00708	CcSEcCtD
Pentazocine—Nystagmus—Doxorubicin—ovarian cancer	0.00556	0.00692	CcSEcCtD
Pentazocine—Muscle spasms—Topotecan—ovarian cancer	0.00548	0.00682	CcSEcCtD
Pentazocine—Confusional state—Chlorambucil—ovarian cancer	0.00527	0.00656	CcSEcCtD
Pentazocine—Flushing—Vinorelbine—ovarian cancer	0.0052	0.00647	CcSEcCtD
Pentazocine—Anorexia—Chlorambucil—ovarian cancer	0.00498	0.0062	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.00491	0.00611	CcSEcCtD
Pentazocine—Cramp muscle—Paclitaxel—ovarian cancer	0.00491	0.00611	CcSEcCtD
Pentazocine—Visual disturbance—Docetaxel—ovarian cancer	0.00487	0.00607	CcSEcCtD
Pentazocine—Anaphylactic shock—Topotecan—ovarian cancer	0.00465	0.00579	CcSEcCtD
Pentazocine—Sweating increased—Paclitaxel—ovarian cancer	0.00459	0.00571	CcSEcCtD
Pentazocine—Anaphylactic shock—Melphalan—ovarian cancer	0.00456	0.00567	CcSEcCtD
Pentazocine—Decreased appetite—Chlorambucil—ovarian cancer	0.00455	0.00566	CcSEcCtD
Pentazocine—Ulcer—Epirubicin—ovarian cancer	0.00454	0.00565	CcSEcCtD
Pentazocine—Hyperhidrosis—Topotecan—ovarian cancer	0.0045	0.0056	CcSEcCtD
Pentazocine—Tachycardia—Melphalan—ovarian cancer	0.00445	0.00554	CcSEcCtD
Pentazocine—Anorexia—Topotecan—ovarian cancer	0.00444	0.00552	CcSEcCtD
Pentazocine—Vertigo—Vinorelbine—ovarian cancer	0.00438	0.00546	CcSEcCtD
Pentazocine—SIGMAR1—lymph node—ovarian cancer	0.00438	0.0223	CbGeAlD
Pentazocine—Anorexia—Melphalan—ovarian cancer	0.00434	0.00541	CcSEcCtD
Pentazocine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00431	0.00536	CcSEcCtD
Pentazocine—Hypotension—Melphalan—ovarian cancer	0.00426	0.0053	CcSEcCtD
Pentazocine—Hypertension—Vinorelbine—ovarian cancer	0.00421	0.00524	CcSEcCtD
Pentazocine—Ulcer—Doxorubicin—ovarian cancer	0.0042	0.00522	CcSEcCtD
Pentazocine—Paraesthesia—Topotecan—ovarian cancer	0.00418	0.0052	CcSEcCtD
Pentazocine—Cramp muscle—Docetaxel—ovarian cancer	0.00416	0.00518	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.00416	0.00518	CcSEcCtD
Pentazocine—Dyspnoea—Topotecan—ovarian cancer	0.00415	0.00516	CcSEcCtD
Pentazocine—Paraesthesia—Melphalan—ovarian cancer	0.00409	0.00509	CcSEcCtD
Pentazocine—Dyspnoea—Melphalan—ovarian cancer	0.00406	0.00506	CcSEcCtD
Pentazocine—Decreased appetite—Topotecan—ovarian cancer	0.00405	0.00504	CcSEcCtD
Pentazocine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00398	0.00496	CcSEcCtD
Pentazocine—Constipation—Topotecan—ovarian cancer	0.00398	0.00495	CcSEcCtD
Pentazocine—Decreased appetite—Melphalan—ovarian cancer	0.00396	0.00493	CcSEcCtD
Pentazocine—Tachycardia—Vinorelbine—ovarian cancer	0.00389	0.00484	CcSEcCtD
Pentazocine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00385	0.00479	CcSEcCtD
Pentazocine—Feeling abnormal—Topotecan—ovarian cancer	0.00384	0.00477	CcSEcCtD
Pentazocine—Anorexia—Vinorelbine—ovarian cancer	0.0038	0.00472	CcSEcCtD
Pentazocine—Asthenia—Chlorambucil—ovarian cancer	0.00375	0.00467	CcSEcCtD
Pentazocine—Hypotension—Vinorelbine—ovarian cancer	0.00372	0.00463	CcSEcCtD
Pentazocine—Pruritus—Chlorambucil—ovarian cancer	0.0037	0.0046	CcSEcCtD
Pentazocine—Visual impairment—Paclitaxel—ovarian cancer	0.00363	0.00452	CcSEcCtD
Pentazocine—Diarrhoea—Chlorambucil—ovarian cancer	0.00358	0.00445	CcSEcCtD
Pentazocine—Paraesthesia—Vinorelbine—ovarian cancer	0.00358	0.00445	CcSEcCtD
Pentazocine—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00356	0.00444	CcSEcCtD
Pentazocine—Erythema multiforme—Paclitaxel—ovarian cancer	0.00356	0.00444	CcSEcCtD
Pentazocine—Dyspnoea—Vinorelbine—ovarian cancer	0.00355	0.00442	CcSEcCtD
Pentazocine—Tinnitus—Paclitaxel—ovarian cancer	0.00351	0.00437	CcSEcCtD
Pentazocine—Flushing—Paclitaxel—ovarian cancer	0.0035	0.00435	CcSEcCtD
Pentazocine—Decreased appetite—Vinorelbine—ovarian cancer	0.00346	0.00431	CcSEcCtD
Pentazocine—Hypersensitivity—Topotecan—ovarian cancer	0.00343	0.00427	CcSEcCtD
Pentazocine—Constipation—Vinorelbine—ovarian cancer	0.0034	0.00424	CcSEcCtD
Pentazocine—Chills—Paclitaxel—ovarian cancer	0.00338	0.00421	CcSEcCtD
Pentazocine—Hypersensitivity—Melphalan—ovarian cancer	0.00336	0.00418	CcSEcCtD
Pentazocine—Asthenia—Topotecan—ovarian cancer	0.00334	0.00416	CcSEcCtD
Pentazocine—Vomiting—Chlorambucil—ovarian cancer	0.00332	0.00414	CcSEcCtD
Pentazocine—Agranulocytosis—Docetaxel—ovarian cancer	0.00332	0.00413	CcSEcCtD
Pentazocine—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.0033	0.0041	CcSEcCtD
Pentazocine—Pruritus—Topotecan—ovarian cancer	0.00329	0.0041	CcSEcCtD
Pentazocine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00328	0.00408	CcSEcCtD
Pentazocine—Asthenia—Melphalan—ovarian cancer	0.00327	0.00407	CcSEcCtD
Pentazocine—Pruritus—Melphalan—ovarian cancer	0.00322	0.00401	CcSEcCtD
Pentazocine—Dysgeusia—Paclitaxel—ovarian cancer	0.00321	0.004	CcSEcCtD
Pentazocine—Diarrhoea—Topotecan—ovarian cancer	0.00318	0.00396	CcSEcCtD
Pentazocine—Muscle spasms—Paclitaxel—ovarian cancer	0.00315	0.00393	CcSEcCtD
Pentazocine—Diarrhoea—Melphalan—ovarian cancer	0.00312	0.00388	CcSEcCtD
Pentazocine—Diplopia—Epirubicin—ovarian cancer	0.00312	0.00388	CcSEcCtD
Pentazocine—Nausea—Chlorambucil—ovarian cancer	0.00311	0.00387	CcSEcCtD
Pentazocine—Vision blurred—Paclitaxel—ovarian cancer	0.00309	0.00385	CcSEcCtD
Pentazocine—Visual impairment—Docetaxel—ovarian cancer	0.00308	0.00383	CcSEcCtD
Pentazocine—Dizziness—Topotecan—ovarian cancer	0.00308	0.00383	CcSEcCtD
Pentazocine—Tremor—Paclitaxel—ovarian cancer	0.00307	0.00383	CcSEcCtD
Pentazocine—Erythema multiforme—Docetaxel—ovarian cancer	0.00302	0.00376	CcSEcCtD
Pentazocine—Agitation—Paclitaxel—ovarian cancer	0.00302	0.00375	CcSEcCtD
Pentazocine—Face oedema—Epirubicin—ovarian cancer	0.00301	0.00374	CcSEcCtD
Pentazocine—Flushing—Docetaxel—ovarian cancer	0.00297	0.00369	CcSEcCtD
Pentazocine—Vomiting—Topotecan—ovarian cancer	0.00296	0.00368	CcSEcCtD
Pentazocine—Vertigo—Paclitaxel—ovarian cancer	0.00295	0.00367	CcSEcCtD
Pentazocine—Syncope—Paclitaxel—ovarian cancer	0.00294	0.00366	CcSEcCtD
Pentazocine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00293	0.00365	CcSEcCtD
Pentazocine—Dermatitis—Topotecan—ovarian cancer	0.00293	0.00365	CcSEcCtD
Pentazocine—Headache—Topotecan—ovarian cancer	0.00292	0.00363	CcSEcCtD
Pentazocine—Vomiting—Melphalan—ovarian cancer	0.0029	0.00361	CcSEcCtD
Pentazocine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00288	0.00359	CcSEcCtD
Pentazocine—Diplopia—Doxorubicin—ovarian cancer	0.00288	0.00359	CcSEcCtD
Pentazocine—Dermatitis—Melphalan—ovarian cancer	0.00287	0.00357	CcSEcCtD
Pentazocine—Chills—Docetaxel—ovarian cancer	0.00287	0.00357	CcSEcCtD
Pentazocine—Asthenia—Vinorelbine—ovarian cancer	0.00286	0.00356	CcSEcCtD
Pentazocine—Hypertension—Paclitaxel—ovarian cancer	0.00283	0.00353	CcSEcCtD
Pentazocine—Pruritus—Vinorelbine—ovarian cancer	0.00282	0.00351	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.00281	0.00349	CcSEcCtD
Pentazocine—Face oedema—Doxorubicin—ovarian cancer	0.00278	0.00346	CcSEcCtD
Pentazocine—Nausea—Topotecan—ovarian cancer	0.00276	0.00344	CcSEcCtD
Pentazocine—Dry mouth—Paclitaxel—ovarian cancer	0.00273	0.0034	CcSEcCtD
Pentazocine—Diarrhoea—Vinorelbine—ovarian cancer	0.00272	0.00339	CcSEcCtD
Pentazocine—Dysgeusia—Docetaxel—ovarian cancer	0.00272	0.00339	CcSEcCtD
Pentazocine—Nausea—Melphalan—ovarian cancer	0.00271	0.00337	CcSEcCtD
Pentazocine—Confusional state—Paclitaxel—ovarian cancer	0.0027	0.00336	CcSEcCtD
Pentazocine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00268	0.00333	CcSEcCtD
Pentazocine—Muscle spasms—Docetaxel—ovarian cancer	0.00267	0.00333	CcSEcCtD
Pentazocine—Eosinophilia—Epirubicin—ovarian cancer	0.00267	0.00332	CcSEcCtD
Pentazocine—Shock—Paclitaxel—ovarian cancer	0.00263	0.00328	CcSEcCtD
Pentazocine—Dizziness—Vinorelbine—ovarian cancer	0.00263	0.00328	CcSEcCtD
Pentazocine—Tachycardia—Paclitaxel—ovarian cancer	0.00261	0.00325	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.0026	0.00323	CcSEcCtD
Pentazocine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00259	0.00322	CcSEcCtD
Pentazocine—Anorexia—Paclitaxel—ovarian cancer	0.00255	0.00318	CcSEcCtD
Pentazocine—Vomiting—Vinorelbine—ovarian cancer	0.00253	0.00315	CcSEcCtD
Pentazocine—Dermatitis—Vinorelbine—ovarian cancer	0.00251	0.00312	CcSEcCtD
Pentazocine—Hypotension—Paclitaxel—ovarian cancer	0.0025	0.00311	CcSEcCtD
Pentazocine—Headache—Vinorelbine—ovarian cancer	0.00249	0.0031	CcSEcCtD
Pentazocine—Syncope—Docetaxel—ovarian cancer	0.00249	0.0031	CcSEcCtD
Pentazocine—Eosinophilia—Doxorubicin—ovarian cancer	0.00247	0.00307	CcSEcCtD
Pentazocine—Loss of consciousness—Docetaxel—ovarian cancer	0.00244	0.00304	CcSEcCtD
Pentazocine—Insomnia—Paclitaxel—ovarian cancer	0.00242	0.00301	CcSEcCtD
Pentazocine—Paraesthesia—Paclitaxel—ovarian cancer	0.0024	0.00299	CcSEcCtD
Pentazocine—Hypertension—Docetaxel—ovarian cancer	0.0024	0.00299	CcSEcCtD
Pentazocine—Dyspnoea—Paclitaxel—ovarian cancer	0.00239	0.00297	CcSEcCtD
Pentazocine—Somnolence—Paclitaxel—ovarian cancer	0.00238	0.00296	CcSEcCtD
Pentazocine—Nausea—Vinorelbine—ovarian cancer	0.00237	0.00294	CcSEcCtD
Pentazocine—Decreased appetite—Paclitaxel—ovarian cancer	0.00233	0.0029	CcSEcCtD
Pentazocine—Dry mouth—Docetaxel—ovarian cancer	0.00232	0.00288	CcSEcCtD
Pentazocine—Sweating—Epirubicin—ovarian cancer	0.0023	0.00286	CcSEcCtD
Pentazocine—Constipation—Paclitaxel—ovarian cancer	0.00229	0.00285	CcSEcCtD
Pentazocine—Confusional state—Docetaxel—ovarian cancer	0.00229	0.00285	CcSEcCtD
Pentazocine—Anaphylactic shock—Docetaxel—ovarian cancer	0.00227	0.00283	CcSEcCtD
Pentazocine—Agranulocytosis—Epirubicin—ovarian cancer	0.00224	0.00279	CcSEcCtD
Pentazocine—Shock—Docetaxel—ovarian cancer	0.00223	0.00278	CcSEcCtD
Pentazocine—Tachycardia—Docetaxel—ovarian cancer	0.00222	0.00276	CcSEcCtD
Pentazocine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00221	0.00275	CcSEcCtD
Pentazocine—Anorexia—Docetaxel—ovarian cancer	0.00216	0.00269	CcSEcCtD
Pentazocine—Sweating—Doxorubicin—ovarian cancer	0.00213	0.00265	CcSEcCtD
Pentazocine—Hypotension—Docetaxel—ovarian cancer	0.00212	0.00264	CcSEcCtD
Pentazocine—Visual impairment—Epirubicin—ovarian cancer	0.00208	0.00258	CcSEcCtD
Pentazocine—Agranulocytosis—Doxorubicin—ovarian cancer	0.00207	0.00258	CcSEcCtD
Pentazocine—Insomnia—Docetaxel—ovarian cancer	0.00205	0.00256	CcSEcCtD
Pentazocine—Paraesthesia—Docetaxel—ovarian cancer	0.00204	0.00254	CcSEcCtD
Pentazocine—Erythema multiforme—Epirubicin—ovarian cancer	0.00204	0.00254	CcSEcCtD
Pentazocine—Dyspnoea—Docetaxel—ovarian cancer	0.00202	0.00252	CcSEcCtD
Pentazocine—Somnolence—Docetaxel—ovarian cancer	0.00202	0.00251	CcSEcCtD
Pentazocine—Tinnitus—Epirubicin—ovarian cancer	0.00201	0.0025	CcSEcCtD
Pentazocine—Flushing—Epirubicin—ovarian cancer	0.002	0.00249	CcSEcCtD
Pentazocine—Decreased appetite—Docetaxel—ovarian cancer	0.00197	0.00246	CcSEcCtD
Pentazocine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00197	0.00246	CcSEcCtD
Pentazocine—Constipation—Docetaxel—ovarian cancer	0.00194	0.00242	CcSEcCtD
Pentazocine—Chills—Epirubicin—ovarian cancer	0.00193	0.00241	CcSEcCtD
Pentazocine—Visual impairment—Doxorubicin—ovarian cancer	0.00192	0.00239	CcSEcCtD
Pentazocine—Asthenia—Paclitaxel—ovarian cancer	0.00192	0.00239	CcSEcCtD
Pentazocine—Pruritus—Paclitaxel—ovarian cancer	0.00189	0.00236	CcSEcCtD
Pentazocine—Erythema multiforme—Doxorubicin—ovarian cancer	0.00189	0.00235	CcSEcCtD
Pentazocine—Feeling abnormal—Docetaxel—ovarian cancer	0.00187	0.00233	CcSEcCtD
Pentazocine—Tinnitus—Doxorubicin—ovarian cancer	0.00186	0.00231	CcSEcCtD
Pentazocine—Flushing—Doxorubicin—ovarian cancer	0.00185	0.0023	CcSEcCtD
Pentazocine—Dysgeusia—Epirubicin—ovarian cancer	0.00184	0.00229	CcSEcCtD
Pentazocine—Diarrhoea—Paclitaxel—ovarian cancer	0.00183	0.00228	CcSEcCtD
Pentazocine—Muscle spasms—Epirubicin—ovarian cancer	0.0018	0.00224	CcSEcCtD
Pentazocine—Chills—Doxorubicin—ovarian cancer	0.00179	0.00223	CcSEcCtD
Pentazocine—Dizziness—Paclitaxel—ovarian cancer	0.00177	0.0022	CcSEcCtD
Pentazocine—Vision blurred—Epirubicin—ovarian cancer	0.00177	0.0022	CcSEcCtD
Pentazocine—Agitation—Epirubicin—ovarian cancer	0.00172	0.00215	CcSEcCtD
Pentazocine—Vomiting—Paclitaxel—ovarian cancer	0.0017	0.00212	CcSEcCtD
Pentazocine—Dysgeusia—Doxorubicin—ovarian cancer	0.0017	0.00212	CcSEcCtD
Pentazocine—Dermatitis—Paclitaxel—ovarian cancer	0.00169	0.0021	CcSEcCtD
Pentazocine—Vertigo—Epirubicin—ovarian cancer	0.00169	0.0021	CcSEcCtD
Pentazocine—Syncope—Epirubicin—ovarian cancer	0.00168	0.00209	CcSEcCtD
Pentazocine—Headache—Paclitaxel—ovarian cancer	0.00168	0.00209	CcSEcCtD
Pentazocine—Hypersensitivity—Docetaxel—ovarian cancer	0.00167	0.00208	CcSEcCtD
Pentazocine—Muscle spasms—Doxorubicin—ovarian cancer	0.00167	0.00208	CcSEcCtD
Pentazocine—Loss of consciousness—Epirubicin—ovarian cancer	0.00165	0.00205	CcSEcCtD
Pentazocine—Vision blurred—Doxorubicin—ovarian cancer	0.00164	0.00204	CcSEcCtD
Pentazocine—Asthenia—Docetaxel—ovarian cancer	0.00163	0.00203	CcSEcCtD
Pentazocine—Hypertension—Epirubicin—ovarian cancer	0.00162	0.00202	CcSEcCtD
Pentazocine—Pruritus—Docetaxel—ovarian cancer	0.00161	0.002	CcSEcCtD
Pentazocine—Agitation—Doxorubicin—ovarian cancer	0.0016	0.00199	CcSEcCtD
Pentazocine—Nausea—Paclitaxel—ovarian cancer	0.00159	0.00198	CcSEcCtD
Pentazocine—Dry mouth—Epirubicin—ovarian cancer	0.00156	0.00194	CcSEcCtD
Pentazocine—Vertigo—Doxorubicin—ovarian cancer	0.00156	0.00194	CcSEcCtD
Pentazocine—Syncope—Doxorubicin—ovarian cancer	0.00156	0.00194	CcSEcCtD
Pentazocine—Diarrhoea—Docetaxel—ovarian cancer	0.00155	0.00193	CcSEcCtD
Pentazocine—Confusional state—Epirubicin—ovarian cancer	0.00154	0.00192	CcSEcCtD
Pentazocine—Anaphylactic shock—Epirubicin—ovarian cancer	0.00153	0.00191	CcSEcCtD
Pentazocine—Loss of consciousness—Doxorubicin—ovarian cancer	0.00153	0.0019	CcSEcCtD
Pentazocine—Shock—Epirubicin—ovarian cancer	0.00151	0.00187	CcSEcCtD
Pentazocine—Dizziness—Docetaxel—ovarian cancer	0.0015	0.00187	CcSEcCtD
Pentazocine—Hypertension—Doxorubicin—ovarian cancer	0.0015	0.00187	CcSEcCtD
Pentazocine—Tachycardia—Epirubicin—ovarian cancer	0.00149	0.00186	CcSEcCtD
Pentazocine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00148	0.00184	CcSEcCtD
Pentazocine—Anorexia—Epirubicin—ovarian cancer	0.00146	0.00182	CcSEcCtD
Pentazocine—Dry mouth—Doxorubicin—ovarian cancer	0.00145	0.0018	CcSEcCtD
Pentazocine—Vomiting—Docetaxel—ovarian cancer	0.00144	0.0018	CcSEcCtD
Pentazocine—Hypotension—Epirubicin—ovarian cancer	0.00143	0.00178	CcSEcCtD
Pentazocine—Dermatitis—Docetaxel—ovarian cancer	0.00143	0.00178	CcSEcCtD
Pentazocine—Confusional state—Doxorubicin—ovarian cancer	0.00143	0.00178	CcSEcCtD
Pentazocine—Headache—Docetaxel—ovarian cancer	0.00142	0.00177	CcSEcCtD
Pentazocine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00142	0.00176	CcSEcCtD
Pentazocine—Shock—Doxorubicin—ovarian cancer	0.00139	0.00173	CcSEcCtD
Pentazocine—Insomnia—Epirubicin—ovarian cancer	0.00138	0.00172	CcSEcCtD
Pentazocine—Tachycardia—Doxorubicin—ovarian cancer	0.00138	0.00172	CcSEcCtD
Pentazocine—Paraesthesia—Epirubicin—ovarian cancer	0.00137	0.00171	CcSEcCtD
Pentazocine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00137	0.0017	CcSEcCtD
Pentazocine—Dyspnoea—Epirubicin—ovarian cancer	0.00137	0.0017	CcSEcCtD
Pentazocine—Somnolence—Epirubicin—ovarian cancer	0.00136	0.00169	CcSEcCtD
Pentazocine—Anorexia—Doxorubicin—ovarian cancer	0.00135	0.00168	CcSEcCtD
Pentazocine—Nausea—Docetaxel—ovarian cancer	0.00135	0.00168	CcSEcCtD
Pentazocine—Decreased appetite—Epirubicin—ovarian cancer	0.00133	0.00166	CcSEcCtD
Pentazocine—Hypotension—Doxorubicin—ovarian cancer	0.00132	0.00165	CcSEcCtD
Pentazocine—Constipation—Epirubicin—ovarian cancer	0.00131	0.00163	CcSEcCtD
Pentazocine—Insomnia—Doxorubicin—ovarian cancer	0.00128	0.00159	CcSEcCtD
Pentazocine—Paraesthesia—Doxorubicin—ovarian cancer	0.00127	0.00158	CcSEcCtD
Pentazocine—Dyspnoea—Doxorubicin—ovarian cancer	0.00126	0.00157	CcSEcCtD
Pentazocine—Feeling abnormal—Epirubicin—ovarian cancer	0.00126	0.00157	CcSEcCtD
Pentazocine—Somnolence—Doxorubicin—ovarian cancer	0.00126	0.00157	CcSEcCtD
Pentazocine—Decreased appetite—Doxorubicin—ovarian cancer	0.00123	0.00153	CcSEcCtD
Pentazocine—Constipation—Doxorubicin—ovarian cancer	0.00121	0.00151	CcSEcCtD
Pentazocine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00117	0.00145	CcSEcCtD
Pentazocine—Hypersensitivity—Epirubicin—ovarian cancer	0.00113	0.0014	CcSEcCtD
Pentazocine—Asthenia—Epirubicin—ovarian cancer	0.0011	0.00137	CcSEcCtD
Pentazocine—Pruritus—Epirubicin—ovarian cancer	0.00108	0.00135	CcSEcCtD
Pentazocine—Diarrhoea—Epirubicin—ovarian cancer	0.00105	0.0013	CcSEcCtD
Pentazocine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00104	0.0013	CcSEcCtD
Pentazocine—Asthenia—Doxorubicin—ovarian cancer	0.00102	0.00126	CcSEcCtD
Pentazocine—Dizziness—Epirubicin—ovarian cancer	0.00101	0.00126	CcSEcCtD
Pentazocine—Pruritus—Doxorubicin—ovarian cancer	0.001	0.00125	CcSEcCtD
Pentazocine—Vomiting—Epirubicin—ovarian cancer	0.000973	0.00121	CcSEcCtD
Pentazocine—Diarrhoea—Doxorubicin—ovarian cancer	0.000969	0.00121	CcSEcCtD
Pentazocine—Dermatitis—Epirubicin—ovarian cancer	0.000964	0.0012	CcSEcCtD
Pentazocine—Headache—Epirubicin—ovarian cancer	0.000959	0.00119	CcSEcCtD
Pentazocine—Dizziness—Doxorubicin—ovarian cancer	0.000937	0.00117	CcSEcCtD
Pentazocine—Nausea—Epirubicin—ovarian cancer	0.000909	0.00113	CcSEcCtD
Pentazocine—Vomiting—Doxorubicin—ovarian cancer	0.000901	0.00112	CcSEcCtD
Pentazocine—Dermatitis—Doxorubicin—ovarian cancer	0.000892	0.00111	CcSEcCtD
Pentazocine—Headache—Doxorubicin—ovarian cancer	0.000888	0.0011	CcSEcCtD
Pentazocine—Nausea—Doxorubicin—ovarian cancer	0.000841	0.00105	CcSEcCtD
